 Home > Active Ingredient News > Antitumor Therapy > Blood: The prognosis of patients with mantle cell lymphoma with positive LRPAP1 autoantibodies is relatively good!

Blood: The prognosis of patients with mantle cell lymphoma with positive LRPAP1 autoantibodies is relatively good!

 Last Update: 2021-06-21
 Source: Internet
 Author: User

Tags

dot hazard class

hazard class 6.1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Central point | LRPAP1 autoantibody is an independent marker of MIPI that can obtain better FFS and OS in patients with mantle cell lymphoma treated with immunochemotherapy

Central point | LRPAP1 autoantibodies is acceptable immune mantle cell chemotherapy of lymphoma patients receive better FFS and OS independent marker of MIPI central point of immunity lymphoma

Low-density lipoprotein (LDL) receptor-related protein-related protein 1 (LRPAP1), confirmed by B cell receptor (BCR) expression cloning and subsequent protein array screening, is a common and possible mantle cell lymphoma (MCL) Autoantigens that induce proliferation
.

Interestingly, high titers and light chain restricted LRPAP1 autoantibodies were detected in 8 of 28 MCL patients

In this study, the researchers analyzed the frequency of LRPAP1 autoantibodies in the serum of MCL patients treated in the young and old trials of the European MCL network, its association with disease characteristics, and its impact on prognosis
.

The frequency of LRPAP1 autoantibodies in the serum of MCL patients, its association with disease characteristics and its influence on prognosis

Titer of LRPAP1 autoantibody

LRPAP1 autoantibodies were detected in 41 (13%) of 312 evaluable MCL patients
.

These LRPAP1 autoantibodies mainly belong to the immunoglobulin G (IgG) class and are restricted by cloned light chains (27 cases of k light chain, 14 cases of lambda light chain)

LRPAP1 autoantibody was detected in 41 (13%) of 312 evaluable MCL patients.

The predictive value of LRPAP1 autoantibodies for prognosis

The presence of LRPAP1 autoantibodies was not significantly correlated with any baseline clinical features ; however, it was more correlated with 5-year treatment failure-free survival (FFS) (70% vs 51%; p=0.
0052), and it was also correlated with excellent The overall survival rate (OS) is related (93% vs 68%; p=0.
0142)
.

The international prognostic adjusted hazard ratios of EFS and OS for mantle cell lymphoma in LRPAP1 seropositive patients were 0.

The presence of LRPAP1 autoantibodies is not significantly correlated with any baseline clinical characteristics.

Patients with seropositive LRPAP1 autoantibodies have better clinical treatment results.

Original source:

Lorenz Thurner, et al.

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.